NCT02821559View on ClinicalTrials.gov

Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2014

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

TOMOX

DRUG

Bevacizumab

Bevacizumab was allowed and used at 7,5 mg/kg or 5 mg/kg every 2 weeks.

Trial Locations (1)

Unknown

CHRU de Besançon, Besançon

All Listed Sponsors
collaborator

Hospira, now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Centre Hospitalier Universitaire de Besancon

OTHER

NCT02821559 - Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter